Pancreatic cancer: Advances and challenges
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
Epithelial and stromal co-evolution and complicity in pancreatic cancer
SR Hingorani - Nature Reviews Cancer, 2023 - nature.com
Pancreatic ductal adenocarcinomas are distinguished by their robust desmoplasia, or
fibroinflammatory response. Dominated by non-malignant cells, the mutated epithelium must …
fibroinflammatory response. Dominated by non-malignant cells, the mutated epithelium must …
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
SB Kemp, N Cheng, N Markosyan, R Sor, IK Kim… - Cancer discovery, 2023 - AACR
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic
ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS G12D) being the most …
ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS G12D) being the most …
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
J Encarnación-Rosado, ASW Sohn, DE Biancur, EY Lin… - Nature cancer, 2024 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …
Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis
The response to tumor-initiating inflammatory and genetic insults can vary among
morphologically indistinguishable cells, suggesting as yet uncharacterized roles for …
morphologically indistinguishable cells, suggesting as yet uncharacterized roles for …
Spatial multi-omics of human skin reveals KRAS and inflammatory responses to spaceflight
Spaceflight can change metabolic, immunological, and biological homeostasis and cause
skin rashes and irritation, yet the molecular basis remains unclear. To investigate the impact …
skin rashes and irritation, yet the molecular basis remains unclear. To investigate the impact …
Oncogenic KRAS drives lipofibrogenesis to promote angiogenesis and colon cancer progression
Oncogenic KRAS (KRAS*) contributes to many cancer hallmarks. In colorectal cancer,
KRAS* suppresses antitumor immunity to promote tumor invasion and metastasis. Here, we …
KRAS* suppresses antitumor immunity to promote tumor invasion and metastasis. Here, we …
Arginase 1 is a key driver of immune suppression in pancreatic cancer
An extensive fibroinflammatory stroma rich in macrophages is a hallmark of pancreatic
cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and …
cancer. In this disease, it is well appreciated that macrophages are immunosuppressive and …
From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts
L Arpinati, R Scherz-Shouval - Trends in Cancer, 2023 - cell.com
Cancer-associated fibroblasts (CAFs) are major protumorigenic components of the tumor
microenvironment in solid cancers. CAFs are heterogeneous, consisting of multiple subsets …
microenvironment in solid cancers. CAFs are heterogeneous, consisting of multiple subsets …
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …